Category: publications

Vaccaro K, Allen J, Whitfield TW, Maoz A, Reeves S, Velarde J, Yang D, Meglan A, Ribeiro J, Blandin J, Phan N, Bell GW, Hata A, Weiskopf K. Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. 2024 Mar 14. doi: 10.1172/JCI169315. Online ahead of print. PMID: 38483480

Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, Langenbucher A, Monroe S, Su W, Cabanos HF, Siddiqui FM, Phan N, Jalili P, Timonina D, Bilton S, Gomez-Caraballo M, Archibald HL, Nangia V, Dionne K, Riley A, Lawlor M, Banwait MK, Cobb RG, Zou L, Dyson NJ, Ott CJ, Benes C, Getz G, Chan CS, Shaw AT, Gainor JF, Lin JJ, Sequist LV, Piotrowska Z, Yeap BY, Engelman JA, Lee JJK, Maruvka YE, Buisson R, Lawrence MS, Hata AN. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature. 2023 Jul 5. doi: 10.1038/s41586-023-06303-1. Online ahead of print. PMID: 37407818

Drilon A, Horan JC, Tangpeerachaikul A, Besse B, Ou SI, Gadgeel SM, Camidge DR, van der Wekken AJ, Nguyen-Phuong L, Acker A, Keddy C, Nicholson KS, Yoda S, Mente S, Sun Y, Soglia JR, Kohl NE, Porter JR, Shair MD, Zhu V, Davare MA, Hata AN, Pelish HE, Lin JJ. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer Discovery. 2023 Mar 1;13(3):598-615. doi: 10.1158/2159-8290.PMID: 36511802

Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BW, Gainor JF, Lin JJ, Yoda S, Hata AN. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer. 2022 Jun 20. doi: 10.1038/s43018-022-00399-6. Online ahead of print.PMID: 35726063

Heather JM, Spindler MJ, Herrero-Alonso M, Shui YI, Millar DG, Johnson DS, Cobbold M, Hata AN. Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information. Nucleic Acids Research. March 24 2022, online ahead of print. doi: 10.1093/nar/gkac190. PMID 35325179

Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, Noeen S, Kattermann K, Greenberg M, Williams A, Riley AK, Wilson JJ, Mao YQ, Huang RP, Banwait MK, Ho J, Crowther GS, Hariri LP, Heist RS, Kodack DP, Pinello L, Shaw AT, Mino-Kenudson M, Hata AN, Sequist LV, Benes CH, Niederst MJ, Engelman JA. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021 Nov 8;39(11):1531-1547.e10. doi: 10.1016/j.ccell.2021.09.003. Epub 2021 Oct 7. PMID: 34624218

Tsai JM, Hata AN, Lennerz JK. MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping. Oncologist. 2021 Dec;26(12):e2297-e2301. doi: 10.1002/onco.13924. PMID: 34347347

Cabanos HF, Hata AN. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers (Basel). 2021 May 28;13(11):2666. doi: 10.3390/cancers13112666. PMID: 34071428.

Tanaka N*, Lin JJ*, Li C*, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN*, Heist RS*, Corcoran RB*. Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation. Cancer Discov. 2021 Apr 6:candisc.0365.2021. doi: 10.1158/2159-8290.CD-21-0365. Online ahead of print. PMID: 33824136

Lin JJ*, Choudhury NJ*, Yoda S*, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN*, Drilon A*, Gainor JF*. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 Mar 8. doi: 10.1158/1078-0432.CCR-21-0032. Epub ahead of print. PMID: 33685866.